Feb. 19, 2020 13:00 UTC

BERKELEY, Calif. & RICHMOND, Calif.--(BUSINESS WIRE)-- Caribou Biosciences, Inc., a leading CRISPR genome editing company, and ProMab Biotechnologies, Inc., a biotechnology CRO/CDMO specializing in antibody engineering and CAR-T development, today announced a sale and assignment agreement under which Caribou gains access to a ProMab humanized single-chain variable fragment (scFv) targeting the B Cell Maturation Antigen (BCMA) for use in allogeneic engineered cell therapies. Caribou intends to utilize this scFv in the development of its CB-011 program, an allogeneic CAR-T therapy targeting BCMA-positive tumors including multiple myeloma.

We are excited for the opportunity to have access to this highly advanced, humanized molecule and believe it will significantly advance our promising CB-011 CAR-T program, said Steven Kanner, PhD, Chief Scientific Officer of Caribou.

We anticipate that our humanized BCMA scFv will aid greatly in Caribous efforts to further its allogeneic CAR-T program, and hope our technology continues to improve the field of preclinical and clinical stage immunotherapy research by providing broad choices of validated antibodies, said John Wu, MD, Chief Executive Officer of ProMab.

Under the terms of the agreement, ProMab received an upfront payment and is eligible for royalties on net sales of licensed products containing the BCMA scFv.

About Caribou Biosciences, Inc. Caribou is a leading company in CRISPR genome editing founded by pioneers of CRISPR-Cas9 biology. The company is developing an internal pipeline of off-the-shelf CAR-T cell therapies, other gene-edited cell therapies, and engineered gut microbes. Additionally, Caribou offers licenses to its CRISPR-Cas9 foundational IP in multiple fields including research tools, internal research use, diagnostics, and industrial biotechnology. Interested companies may contact Caribou at licensing@cariboubio.com. For more information about Caribou, visit http://www.cariboubio.com and follow the Company @CaribouBio. Caribou Biosciences and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

About ProMab Biotechnologies, Inc. ProMab Biotechnologies focuses on developing and commercializing mouse, rabbit, and human monoclonal antibodies as well as chimeric antigen receptor-T Cell (CAR-T) products. ProMabs CAR-T platform covers both hematological and solid cancers with intensive in vitro and in vivo pre-clinical validation designed for safer and better treatment. As a CRO in the immunology field for 19 years, ProMab offers standard laboratory procedures and animal studies for antibody discovery through the integration of the newest techniques in antibody library construction, next generation sequencing, unique humanization modeling, high-throughput screening, and artificial intelligence analysis systems. ProMab aims to out-license antibodies validated in CAR-T therapy in the preclinical stage or to bring CAR-T technologies to the early stage market of clinical study. ProMab has partnered with top biotechnology startups, medical institutions, and pharmaceutical companies to advance the development of cell therapies as well as bispecific antibodies targeting multiple cancers. For more information, visit http://www.promab.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200219005112/en/

See the original post here:
Caribou Biosciences and ProMab Biotechnologies Announce Sale and Assignment Agreement for Humanized scFv Targeting BCMA - BioSpace

Recommendation and review posted by Bethany Smith

Zacks Investment Research upgraded shares of Crispr Therapeutics (NASDAQ:CRSP) from a sell rating to a hold rating in a research report sent to investors on Monday, Zacks.com reports.

According to Zacks, CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

Other research analysts have also recently issued research reports about the stock. Needham & Company LLC reiterated a buy rating and set a $84.00 price target on shares of Crispr Therapeutics in a research note on Monday, December 23rd. Chardan Capital reiterated a buy rating and set a $72.50 price target on shares of Crispr Therapeutics in a research note on Thursday, February 13th. Canaccord Genuity lifted their price target on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the stock a positive rating in a research note on Wednesday, November 20th. TheStreet upgraded shares of Crispr Therapeutics from a d rating to a c rating in a research note on Monday, October 28th. Finally, William Blair reiterated a buy rating on shares of Crispr Therapeutics in a research note on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and thirteen have assigned a buy rating to the companys stock. The stock presently has an average rating of Buy and a consensus price target of $78.29.

Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Wednesday, February 12th. The company reported $0.51 earnings per share (EPS) for the quarter, topping the Thomson Reuters consensus estimate of ($0.68) by $1.19. The company had revenue of $77.00 million for the quarter, compared to analysts expectations of $39.08 million. Crispr Therapeutics had a net margin of 23.09% and a return on equity of 11.74%. The firms quarterly revenue was up 76900.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.92) earnings per share. On average, analysts predict that Crispr Therapeutics will post -4.61 EPS for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CRSP. Nikko Asset Management Americas Inc. lifted its stake in shares of Crispr Therapeutics by 48.4% during the 3rd quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the companys stock valued at $113,846,000 after buying an additional 906,006 shares in the last quarter. Orbimed Advisors LLC purchased a new position in shares of Crispr Therapeutics during the 3rd quarter valued at $21,167,000. FMR LLC lifted its stake in shares of Crispr Therapeutics by 71.8% during the 4th quarter. FMR LLC now owns 952,369 shares of the companys stock valued at $58,004,000 after buying an additional 398,012 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Crispr Therapeutics by 904.0% during the 4th quarter. Renaissance Technologies LLC now owns 394,564 shares of the companys stock valued at $24,031,000 after buying an additional 355,264 shares in the last quarter. Finally, ARK Investment Management LLC lifted its stake in shares of Crispr Therapeutics by 6.3% during the 4th quarter. ARK Investment Management LLC now owns 2,956,635 shares of the companys stock valued at $180,074,000 after buying an additional 174,495 shares in the last quarter. Institutional investors own 51.28% of the companys stock.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Read More: What is a Call Option?

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

View post:
Crispr Therapeutics (NASDAQ:CRSP) Upgraded to Hold by Zacks Investment Research - Enterprise Echo

Recommendation and review posted by Bethany Smith

Global CRISPR/Cas9 Market research report gives a comprehensive outlook of the markets 2019-2025 and offers an in-depth summary of the current market status, historic, and expected way forward for the CRISPR/Cas9 Market. Additionally, to this, the report provides data on the restraints negatively impacting the markets growth. The report includes valuable information to assist new entrants, as well as established players, to understand the prevailing trends in the Market.

Download Free Sample Copy of CRISPR/Cas9 Market Report: https://dataintelo.com/request-sample/?reportId=103652

Key Objectives of CRISPR/Cas9 Market Report: Study of the annual revenues and market developments of the major players that supply CRISPR/Cas9 Analysis of the demand for CRISPR/Cas9 by component Assessment of future trends and growth of architecture in the CRISPR/Cas9 Market Assessment of the CRISPR/Cas9 Market with respect to the type of application Study of the market trends in various regions and countries, by component, of the CRISPR/Cas9 Market Study of contracts and developments related to the CRISPR/Cas9 Market by key players across different regions Finalization of overall market sizes by triangulating the supply-side data, which includes product developments, supply chain, and annual revenues of companies supplying CRISPR/Cas9 across the globe

Major Players included in this report are as follows Caribou BiosciencesIntegrated DNA Technologies (IDT)CRISPR TherapeuticsMerckMirus BioEditas MedicineTakara BioThermo Fisher ScientificHorizon Discovery GroupIntellia TherapeuticsAgilent TechnologiesCellectaGenScriptGeneCopoeiaSynthego

CRISPR/Cas9 Market can be segmented into Product Types as Genome EditingGenetic engineeringgRNA Database/Gene LibrarCRISPR PlasmidHuman Stem CellsGenetically Modified Organisms/CropsCell Line Engineering

CRISPR/Cas9 Market can be segmented into Applications as Biotechnology CompaniesPharmaceutical CompaniesAcademic InstitutesResearch and Development Institutes

To Buy this report, Visit https://dataintelo.com/checkout/?reportId=103652

CRISPR/Cas9 Market: Regional analysis includes: Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) North America (United States, Mexico, and Canada.) South America (Brazil etc.) The Middle East and Africa (GCC Countries and Egypt.)

Target Audience: CRISPR/Cas9 Equipment Manufacturers Traders, Importers, and Exporters Raw Material Suppliers and Distributors Research and Consulting Firms Government and Research Organizations Associations and Industry Bodies

Stakeholders, marketing executives and business owners planning to refer a market research report can use this study to design their offerings and understand how competitors attract their potential customers and manage their supply and distribution channels. When tracking the trends researchers have made a conscious effort to analyse and interpret the consumer behaviour. Besides, the research helps product owners to understand the changes in culture, target market as well as brands so they can draw the attention of the potential customers more effectively.

Customize Report and Inquiry for The CRISPR/Cas9 Market Report: https://dataintelo.com/enquiry-before-buying/?reportId=103652

Report structure: In the recently published report, DataIntelo.com has provided a unique insight into the CRISPR/Cas9 Industry over the forecasted period. The report has covered the significant aspects which are contributing to the growth of the global CRISPR/Cas9 Market. The primary objective of this report is to highlight the various key market dynamics listed as drivers, trends, and restraints.

These market dynamics have the potential to impact the global CRISPR/Cas9 Market. This report has provided the detailed information to the audience about the way CRISPR/Cas9 industry has been heading since past few months and how it is going to take a shape in the years to come.

DataIntelo has offered a comprehensive analysis of the CRISPR/Cas9 industry. The report has provided crucial information about the elements that are impacting and driving the sales of the CRISPR/Cas9 Market. The section of competitive landscape keeps utmost importance in the reports published by DataIntelo. Competitive landscape section consists of key market players functioning in the worldwide industry of CRISPR/Cas9.

The report has also analysed the changing trends in the industry. Several macroeconomic factors such as Gross domestic product (GDP) and the increasing inflation rate is expected to affect directly or indirectly in the development of the CRISPR/Cas9 Market.

Table of Contents 1 Industry Overview of CRISPR/Cas9 2 Manufacturing Cost Structure Analysis 3 Development and Manufacturing Plants Analysis of CRISPR/Cas9 4 Key Figures of Major Manufacturers 5 CRISPR/Cas9 Regional Market Analysis 6 CRISPR/Cas9 Segment Market Analysis (by Type) 7 CRISPR/Cas9 Segment Market Analysis (by Application) 8 CRISPR/Cas9 Major Manufacturers Analysis 9 Development Trend of Analysis of CRISPR/Cas9 Market 10 Marketing Channel 11 Market Dynamics 12 Conclusion 13 Appendix

Ask for Discount on CRISPR/Cas9 Market Report at: https://dataintelo.com/ask-for-discount/?reportId=103652

About DataIntelo: DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info DataIntelo Name Alex Mathews Email [emailprotected] Website https://dataintelo.com Address 500 East E Street, Ontario, CA 91764, United States.

Read more here:
CRISPR/Cas9 Market Demand Analysis and Projected huge Growth by 2025 - News Parents

Recommendation and review posted by Bethany Smith

Reports Monitors report on the global CRISPR Technology market studies past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the CRISPR Technology market during the forecast period from 2019 to 2024. The report provides the overall global market statistics of the global CRISPR Technology market for the period of 20192024, with 2018 as the base year and 2024 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global CRISPR Technology market during the forecast period.

SWOT Analysis of Leading Contenders covered in this report:- Thermo Fisher Scientific, Merck KGaA, GenScript, Integrated DNA Technologies (IDT), Horizon Discovery Group, Agilent Technologies, Cellecta, GeneCopoeia, New England Biolabs, Origene Technologies, Synthego Corporation, Toolgen and more.

Get access to sample report, Click here @https://www.reportsmonitor.com/request_sample/584056

The global CRISPR Technology market was xx million US$ in 2018 and is expected to xx million US$ by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.

This report studies the CRISPR Technology market size (value and volume) by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2024; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porters Five Forces Analysis.

Product Type Segmentation:-

EnzymesKitsgRNALibrariesDesign Tools

Industry Segmentation:-

BiomedicalAgricultural

The CRISPR Technology market report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on changing competitive dynamics in the global CRISPR Technology market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global CRISPR Technology market.

Get a discount on this report@https://www.reportsmonitor.com/check_discount/584056

The report reaches inside into the competitive landscape of the global CRISPR Technology market. Key players operating in the global CRISPR Technology market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of players in the global CRISPR Technology market that have been profiled in this report.

Regional Coverage:-

The report has been prepared after extensive primary and secondary research. Primary research involves the bulk of research efforts wherein, analysts carry out interviews with industry leaders and opinion-makers. Extensive secondary research involves referring to key players product literature, annual reports, press releases, and relevant documents to understand the global CRISPR Technology market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomena in the global CRISPR Technology market.

Key Questions Answered in CRISPR Technology Market Report

View this report with a detailed description and TOC @ https://www.reportsmonitor.com/report/584056/CRISPR-Technology-Market

Contact UsJay MatthewsDirect: +1 513 549 5911 (U.S.)+44 203 318 2846 (U.K.)Email: [emailprotected]

Read the original post:
CRISPR Technology Market Analysis with Key Players, Applications, Trends and Forecasts to 2025 | Thermo Fisher Scientific, Merck KGaA, GenScript -...

Recommendation and review posted by Bethany Smith

European Pharmaceutical Review explores how plants can be used for large-scale, glycosylated protein bioproduction for the pharma industry.

Plants can be used to produce large quantities of complex proteins, particularly glycosylated proteins, which are becoming more widely used in a range of therapies. Monoclonal antibodies (mAbs) are among the types of glycosylated proteins that plants can produce, but while there are multiple benefits to their use as bioreactors, there are also some key considerations.

This article explores why and how plants can be used to produce proteins for use in therapies, but also the factors that show this method may not be applicable to all protein products.

For plants to produce synthetic proteins, they must first be expressed somewhere within their genome. This requires some form of recombinant protein expression or genetic engineering, and to achieve optimum yield just implanting the gene is insufficient. To achieve a high level of transcription, which allows for downstream translation and protein modification for stability, the regulatory gene elements including the promoter and polyadenylation site must also be expressed.1

Techniques for gene expression:

There are three commonly used types of expression mechanisms for plant bioproduction: nuclear, chloroplast and transient expression.

Nuclear expression involves genetically modifying the genome in the nuclei of plants cells to express a protein. This is the simplest and most widely used approach in the pharmaceutical industry, as it can be achieved with viral vectors, but a more modern technique is CRISPR-Cas9 technologies.1 A 2018 study showed that in cotton, CRISPR showed no offtarget editing and an editing efficiency of 66.7 to 100 percent at each of multiple sites.2 The nuclear expression techniques, although reliable, are becoming less popular as they typically require more time to develop.

The second method involves expression of a recombinant protein in the chloroplasts requires a particle gun to insert the transgene. There are several benefits to this technique, including the ease of manipulating the chloroplast genome compared with the nucleus and the number of chloroplasts per cell, which increases yield. Using a transgene cassette to precisely target and insert the foreign gene avoids placing it into a poorly transcribed part of the genome, ensuring a high level of expression and little chance of silencing. Transgenes are commonly integrated between the trnltrnA genes in the rrn operon, as this is a transcriptionally active region offering high levels of gene expression.1

The third mechanism, transient expression, is becoming more common as it allows the rapid insertion of proteins, with little time required for the production, modification and optimisation of the expression system. Some companies have begun marketing this kind of expression for the rapid, large-scale production of proteins for therapeutics. The Agrobacteriummediated transient expression technique is purported to have better efficiency than the integrated gene systems and the ability to reach a high percentage of cells in a treated tissue, resulting in higher yields.1

In prokaryotic cells, like Escherichia coli (E. coli), protein size is limited to less than 30 kilodaltons, mainly due to reliability of production and yield. However, in eukaryotic cells, eg, Chinese hamster ovary (CHO) andplant cells, it is easier to produce larger proteins with high yields.1

According to experts, when using cell line or bacterial production methods such as CHO cells and E. coli to produce proteins, once the initial cell line is created it is often difficult to scale up, as glycosylation profiles become variable.3 The inconsistencies in protein product both cost money and result in waste.

On the other hand, dependent on expression mechanisms, plants can reliably maintain the glycosylation profile required even as bioreactor volume increases.

As a result of consistent production capabilities, plants do not require scale-up protocols. This saves both time and money when setting up a bioreactor.

A further advantage is that, if the plant is made to generate the protein through a transient expression system, there is very little time required to set up a production system. One company claims their tobacco plant-based system can be tailored for large-scale fabrication of a protein product in under 12 months, compared to 20-22 months with CHO or E. coli, 3 and one study suggests this could be done in a matter of weeks.1

There are multiple options for plant expression systems, particularly with regards to species, and each is best suited to produce different proteins. Genetic engineering can also be employed to allow customised N-glycosylation to generate different target products.

The plant industry is well established, with conditions for growth often being less complex than that of cell lines or bacteria and, dependent on choice of plant species, cultivation costs can be further reduced.

A techno-economic analysis of the theoretical set-up of a new large-scale biomanufacturing facility, producing mAbs using tobacco plants, found that compared to CHO production platforms, the plant system resulted in significantly reduced capital investment. Moreover, the model calculated that there would be more than a 50 percent reduction in the cost of goods, compared with published values for similar products at this production scale.4

One company has paved the way for the creation of biobetters, using their FastGlycaneering Development Service. iBio has shown that certain methods of plant bioproduction can improve the potency and homogeneity of biological medicines and ensure fully humanised glycosylation patterns.

iBio have also stated that their system, due to its consistencies in upstream processing, is compatible with artificial intelligence (AI). The company aim to implement a new end-to-end manufacturing process using AI and blockchain to reduce costs through optimising both the process and workflows.3

Some of the major challenges include regulatory approval, environmental contamination, protein stability and the immunogenicity of non-human post-translational modifications.1

Environmental concerns are predominantly from the possibility of spreading genetic modifications to food crops through pollination. This is more of a concern with the nuclear expression systems than transient or chloroplast expression. However, this can be overcome with geographical or physical containment, using a less transferable genetic modification method or through using a self-pollenating species.1

A review suggested that companies are unlikely to go through the cost of a shift from an already approved production system to seek regulatory approval for a new one.1 While altering an approved process is often unfeasible, setting up systems for the production of new products in the pipeline could prove to be more cost effective in the long run. Another consideration is the rising need for quick, large-scale vaccine production in response to pandemics and epidemics such as the Covid-19 coronavirus and Ebola which, due to the speed at which a transient expression production system can be constructed, could encourage companies to branch into this type of production.

Protein stability is a concern, as plants have endogenous enzymes that can break down the protein products. Some methods to overcome this include changing plant species and co-expressing peptides to fuse and stabilise the produced proteins together.

Post-translational modifications such as Asparagine-linked glycosylation (N-glycosylation) are one of the key worries, as they can be immunogenic. Particularly likely to cause unfavourable side effects are N-glycan modifications, because they differ in plants and humans.

N-glycosylation is a post-translational modification conducted on many secreted or membrane proteins in plants and mammals. Endogenously, it enables protein folding, stabilisation and protein-protein interactions. It is similarly used in pharmaceutical bioproduction to stabilise products and provide antibodies and other proteins the correct pharmacokinetic properties and immunogenicity.5,6

The plant industry is well established, with conditions for growth often being less complex than that of cell lines or bacteria

While early N-glycosylation and N-glycan modifications are highly conserved between yeast, mammals and plants, later N-glycan modifications differ; they are more simplified in plants than mammals.5,6 So, to use plants as producers of fully humanised proteins, the plant glycosylation machinery is often removed and replaced with human machinery when the plant is modified to express the protein. Of note, chloroplasts have no glycosylation machinery, so cannot perform these modifications without the insertion of foreign DNA; although this can reduce immunogenicity of the products, it can limit which proteins can be produced by chloroplast expression.

Tobacco is the most widely used plant for production of recombinant proteins in the lab. High yield and rapid scale-up, due to large numbers of seeds produced, are the primary benefits. However, proteins stored in the leaves are vulnerable to degradation and must be stored or extracted appropriately, in a timely manner. Tobacco tissues can also contain phenols and toxic alkaloids that must be removed in downstream processing to make products safe.1

Cereals are primarily used due to their seed protein storage capabilities; cereal seeds have protein storage vesicles and a dry intracellular environment. Once dried, the seeds can be stored at room temperature with limited degradation to protein products or loss of activity. Use of food crops is particularly attractive as they offer the opportunity to administer oral vaccines produced in the crop by feeding them to patients with minimal processing. Some edible vaccines have reached Phase I trials.1

Peas are a particularly attractive option, as they have high protein content in their seeds similar to cereals and have lower nitrogen requirements, reducing cultivation costs. However, legumes usually have less leaf biomass than tobacco, meaning they require a larger area to produce the same quantity.1

Plants can be modified through several methods to express proteins and the requisite promoters and transcription controllers, for the production of therapeutic proteins. There are several important considerations, including protein expression methods and plant species; however, the many benefits, including reduced costs, adaptability and speed associated with plant bioproduction systems make them an attractive option.

A particular driver of this bioproduction process is the possibility of using transient expression to produce vast quantities of highly potent, fully humanised vaccines in response to pandemics and epidemics.

iBio

See the rest here:
Using plants as bioreactors to produce proteins for therapeutics - European Pharmaceutical Review

Recommendation and review posted by Bethany Smith

Sifting through a soup of genes sampled from many environments, including human saliva, animal poop, lakes, hospitals, soils and more, researchers have found hundreds of giant viruses - some with abilities only seen before in cellular life.

The international team, led by scientists from University of California, Berkeley, has discovered entire new groups of giant phages (viruses that infect bacteria) and pieced together 351 gene sequences.

Within these they found genes that code for unexpected things, including bits of the cellular machinery that reads and executes DNA instructions to build proteins, also known as translation.

"They have an unusual number of components of the translation machinery that you do not find on a typical virus," microbiologists Basem Al-Shayeb and Jill Banfield from UC Berkeley told ScienceAlert.

The translation process takes place in molecular structures known as ribosomes, and the researchers actually found genes that code for some of their components - ribosomal proteins.

"Typically, what separates life from non-life is to have ribosomes and the ability to do translation; that is one of the major defining features that separates viruses and bacteria, non-life and life," said microbial ecologist Rohan Sachdeva from UC Berkeley.

"Some large phages have a lot of this translational machinery, so they are blurring the line a bit."

The team also found sequences for CRISPR systems, which also happens to be the 'immune system' bacteria use against viruses, the very same system we humans have co-opted for our own gene manipulation purposes.

The newly discovered viruses all have genomes more than 200,000 base pairs long, whereas the average known phage size is more along the lines of 52,000 base pairs.

Some phage genomes identified by the team were true whoppers; the researchers have named one group Whopperphage, and designated the other nine new groups after the word "big" in the different languages of the contributing authors.

"The genomes of these phages are at least four times the size of a typical phage, and the largest is 15 times larger - 735,000 bases of DNA," Al-Shayeb and Banfield said.

These larger phages are thought to infect Bacteroidetes, a group of bacteria widely dispersed in our environment, from soil to our intestines.

The genomes of these hefty phages are large enough to rival those of small bacteria, but the amoeba-infecting pandoraviruses still hold the title of the largest viral genome at 2.5 million base pairs.

"Large phages have been found before, but they were spot findings," Sachdeva told the Innovative Genomics Institute. "What we found in this paper is they are essentially ubiquitous. We find them everywhere."

Like other phages, these chonkers inject their DNA into their bacterial host, hijacking the victim's gene replication equipment to make copies of themselves.

The researchers suspect that while this is happening, the giants also use some of their additional genes to derail early stages of translation inside the bacteria, and divert protein production to suit their own needs. Such control of protein creation has also been observed in animal viruses.

Al-Shayeb explained that giant phages use their CRISPR system for phage-on-phage warfare, by specifically targeting competing viruses that try to infect the same host bacterium. A study from last year shows how some phages use this system to thwart anti-phage measures their host bacteria may deploy.

A huge phage (Subject 26) infecting a bacterium and manipulating its response to other phages. (Jill Banfield Lab/UC Berkeley)

"The sense we have looking at these large genomes is that phages have acquired a lot of different genes and pathways - some of which we can predict, some of which we can't for really taking control of bacterial hosts' function during infection," Banfield told the Innovative Genomics Institute.

As we learn more about the links between our physical and mental health and the microbes we share our bodies and environments with, it is clear that what affects them can also profoundly impact us.

"Phages are also known to transfer genes for bacterial toxins and antibiotic resistance between bacteria, which contribute to disease," Al-Shayeb said.

"Since we have both harmful and useful bacteria living on us and within us, understanding what kinds of phages coexist with them in humans and animals and how they affect those environments is of great value."

The researchers suggest that the interesting CRISPR systems some of these phages possess may have the potential to help us control our own microbiomes, by altering the function of bacteria or eliminating the troublesome ones.

They now hope to grow some of these whopper phages in the lab, to learn more about these phage-associated CRISPR systems and "discover their roles and test for value in genome editing", according to Al-Shayeb and Banfield.

Biochemist Christoph Weigel, who was not associated with the study, suggested on Twitter that the paper provides "strong support" for considering viruses living "virocells".

"These huge phages bridge the gap between non-living bacteriophages, on the one hand, and bacteria and Archaea," explained Banfield.

"There definitely seem to be successful strategies of existence that are hybrids between what we think of as traditional viruses and traditional living organisms."

Whatever else this huge addition to our knowledge of viral biodiversity brings, it's already sparking further discussion on what it means to be alive.

This study was published in Nature.

Read more:
Scientists Discover Giant Viruses With Features Only Seen Before in Living Cells - ScienceAlert

Recommendation and review posted by Bethany Smith

According to researchers, a certain bacterial strain has acquired a new gene that makes it able to resist antibiotics via the DNA sequence known as CRISPR, clustered regularly interspaced short palindromic repeats (not to be confused with the CRISPR gene-editing technology).

Bacteria acquire CRISPR sequences from infecting viruses called bacteriophages, which insert fragments of DNA into bacterial genomes, the University of Washington School of Medicine, which was involved in the study, reported in a news release explaining how bacteria get these pieces of DNA via viral infection. (Yes, even bacteria can get a viral infection.) These bacteriophages hijack their host system to reproduce and can leave bits of DNA behind. In this case the CRISPR sequence appears to have included the drug-resistance gene.

The recent study, led by Dr. Alex Greninger, assistant professor of laboratory medicine at the UW School of Medicine, discovered nearly identical bacteria among these unrelated men in the two cities, and concluded it is likely being transmitted by men who have sex with men.

Campylobacter is one of the most common causes of diarrhea around the world. In fact, according to a Centers for Disease Control and Prevention estimate, it causes 1.5 million illnesses in the United States every year. People usually recover without treatment, but those with serious cases or compromised health require antibiotics. What makes this new strain particularly dangerous is that it is resistant to those antibiotics used for treatment.

Enteric infections can be sexually transmitted infections, Greninger said in the press release, about the intestinal infections that can be transmitted via anal intercourse, rimming, or other sexual practices. The international spread of related isolates among MSM populations has been shown before for Shigella, so it makes sense to see it in Campylobacter as well. The group of bacteria called Shigella cause about 500,000 cases of diarrhea in the United States annually, and outbreaks among gay and bisexual men have been noted for two decades.

Men who have sex with men are at higher risk of multidrug resistance because theyre more likely to have taken antibiotics to treat past STIs, the authors of the new study state. According to MedScape, Campylobacter infections may be more common and cause prolonged or recurrent diarrhea among those living with HIV.

While STI rates have increased significantly over the last few years, less is known about STIs related to intestinal bacteria. This outbreak among gay and bisexual men with a strain that is resistant to antibiotics raises the stakes.

The global emergence of multidrug-resistant enteric pathogens in MSM poses an urgent public health challenge that may require new approaches for surveillance and prevention, the authors concluded.

Read more:
Gay and Can't Stop Pooping? This Could Be Why - HivPlusMag.com

Recommendation and review posted by Bethany Smith

Medical treatment involving stem cells is an ever-growing, billion-dollar industry, so chances are you have heard about it in the news. Here in the U.S. and around the world, stem cells are being used in various therapies to treat a wide variety of health problems and diseases, including dementia, autism, multiple sclerosis, cerebral palsy, osteoarthritis, cancer, heart disease, Parkinsons disease, and spinal cord injury. Treatments for such health issues may sound promising, but the risk is many of those being sold and advertised arent yet proven to be safe and effective. This is why its so important to educate yourself before jumping into any kind of stem cell treatment.

To gain a better understanding of this new age of medical research, one must first understand what stem cells are and how they work. Stem cells are special human cells that can develop into many different types of cells. They can divide and produce more of the same type of stem cells, or they can turn into different functioning cells. There are no other types of cells in the body that have this natural ability to generate new cell types.

So where do stem cells that are used for research and medical treatments come from? The three main types of stem cells are embryonic (or pluripotent) stem cells, adult stem cells, and induced pluripotent stem cells.

Embryonic stem cells come from unused, in vitro fertilized embryos that are three to five days old. The embryos are only donated for research purposes with the informed consent of the donors. Embryonic stem cells are pluripotent, which means they can turn into any cell type in the body.

Adult stem cells are found in small numbers in developed tissues in different parts of the body, such as bone marrow, skin, and the brain. They are specific to a certain kind of tissue in the body and are limited to maintaining and repairing the tissue in which they are found. For example, liver stem cells can only make new liver tissue; they arent able to make new muscle tissue.

Induced pluripotent stem cells are another form of adult stem cells. These are stem cells that have been manipulated in a laboratory and reprogrammed to work like embryotic (or pluripotent) stem cells. While these altered adult stem cells dont appear to be clinically different from embryonic stem cells, research is still being conducted to determine if the effects they have on humans differ from actual embryonic stem cells.

Stem cells can also be found in amniotic fluid and umbilical cord blood. These stem cells have the ability to change into specialized cells like embryonic stem cells. While more research is being conducted to determine the potential of these types of stem cells, researchers already actively use these through amniocentesis procedures. In this procedure, the stem cells drawn from amniotic fluid samples of pregnant women can be screened for developmental abnormalities in a fetus.

The main difference between embryonic and adult stem cells is how they function. Embryonic stem cells are more versatile. Since they can divide into more stem cells or become any type of cell in the body, they can be used to regenerate or repair a variety of diseased tissue and organs. Adult stem cells only generate the types of cells from where they are taken from in the body.

The ability for stem cells to regenerate under the right conditions in the body or in a laboratory is why researchers and doctors have become so interested in studying them. Stem cell research is helping scientists and doctors to better understand how certain diseases occur, how to possibly generate healthy cells to replace diseased cells, and offer ways to test new drugs.

Clearly, stem cell research is showing great potential for understanding and treating a range of diseases and other health issues, but there is still a lot to learn. While there are some diseases that are showing success using stem cell treatments, many others are yet to be proven in clinical trials and should be considered highly experimental.

In our next article, various stem cell treatments, FDA regulations, and other stem cell hot topics will be explored. It will also focus on what to look for when considering stem cell therapies so people arent misled or misinformed about the benefits and risks.

For more information regarding the basics of stem cells visit these sites:

https://stemcells.nih.gov/info/basics/1.htm

https://www.mayoclinic.org/tests-procedures/bone-marrow-transplant/in-depth/stem-cells/art-20048117

Continued here:
The 411 on Stem Cells: What They Are and Why It's Important to Be Educated - Legal Examiner

Recommendation and review posted by Bethany Smith

DURHAM, N.C., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Chimerix(CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Tuesday, February 25, 2020 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2019, and to provide a business overview.

To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 1397800. A live audio webcast of the call will also be available on the Investors section of the Company's website, http://www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.

AboutChimerix

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. The two clinical-stage development programs are dociparstat sodium (DSTAT) and brincidofovir (BCV).

Dociparstat sodium is a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of several key proteins implicated in the retention and viability of AML blasts and leukemic stem cells in the bone marrow during chemotherapy (e.g., CXCL12, selectins, HMGB1, elastase). Mobilization of AML blasts and leukemic stem cells from the bone marrow has been associated with enhanced chemosensitivity and may be a primary mechanism accounting for the observed increases in EFS and OS in Phase 2 with DSTAT versus placebo. Randomized Phase 2 data suggest that DSTAT may also accelerate platelet recovery post-chemotherapy via inhibition of platelet factor 4, a negative regulator of platelet production that impairs platelet recovery following chemotherapy. BCV is an antiviral drug candidate in development as a medical countermeasure for smallpox. For further information, please visit the Chimerix website, http://www.chimerix.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, Chimerixs ability to develop BCV as a medical countermeasure for smallpox; Chimerixs ability to submit and/or obtain regulatory approvals for BCV; and Chimerixs ability to enter into a procurement contract for BCV as a medical countermeasure. Among the factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are risks that BCV may not obtain regulatory approval from theFDAor such approval may be delayed or conditioned; risks that development activities related to BCV may not be completed on time or at all; Chimerixs reliance on a sole source third-party manufacturer for drug supply; risks that ongoing or future trials may not be successful or replicate previous trial results, or may not be predictive of real-world results or of results in subsequent trials; risks and uncertainties relating to competitive products and technological changes that may limit demand for our drugs; risks that our drugs may be precluded from commercialization by the proprietary rights of third parties; risks related to procurement of brincidofovir for the treatment of smallpox and additional risks set forth in the Company's filings with theSecurities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

CONTACT:Investor Relations: Michelle LaSpaluto919 972-7115ir@chimerix.com

Will OConnorStern Investor Relationswill@sternir.com 212-362-1200

Story continues

Read the rest here:
Chimerix to Report Fourth Quarter and Year End 2019 Financial Results and Provide an Operational Update on February 25, 2020 - Yahoo Finance

Recommendation and review posted by Bethany Smith

NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announces financial results for fiscal year ended December 31, 2019.

2019 was a tremendous year for BrainStorm, with significant progress and achievements across all clinical and operational fronts, stated Chaim Lebovits, President and Chief Executive Officer of BrainStorm. Most importantly, we fully enrolled our pivotal, double blind, placebo-controlled Phase 3 trial of NurOwn for the treatment of ALS. We announced the trial conducted at six major U.S. medical centers of excellence for ALS, was fully enrolled on October 11, 2019, and on October 28, 2019 the Data and Safety Monitoring Board (DSMB), completed the second planned interim safety analysis for the first 106 patients who received repeat dosing of NurOwn in the Phase 3 trial. The DSMB concluded the trial should continue as planned without any clinical protocol changes. He added, In addition, one of the most prestigious peer-reviewed journals, Neurology, published NurOwn Phase 2 Randomized Clinical Trial in ALS: Safety, Clinical and BioMarker Results, bringing news of our investigational therapy to the global scientific community. And, just last week, we were happy to announce that the Company recently held a high level meeting with the U.S. Food and Drug Administration (FDA) to discuss potential NurOwn regulatory pathways for approval in ALS.

Ralph Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer of BrainStorm added, 2019 was also a very significant year for those who suffer from progressive Multiple Sclerosis (MS). In February 2019, we announced Cleveland Clinic would serve as our first contracted site for a Phase 2 open-label, multicenter study of repeated intrathecal administration of NurOwn (autologous MSC-NTF cells) in participants with progressive MS (NCT03799718). We enrolled our first patient in March. We contracted with The Stanford University School of Medicine, The Keck School of Medicine of the University of Southern California, and the Mount Sinai Medical Center to further enroll patients. Dr. Kern added, The importance of our research in progressive MS was acknowledged by a $495,000 grant award from the National Multiple Sclerosis Society through its Fast Forward Program, and mid-December, the Data Safety Monitoring Board completed the first, pre-specified interim analysis, of safety outcomes for 9 participants and after careful review of all available clinical trial data, the DSMB unanimously concluded that the study should continue as planned without any protocol modification. As of December 31, 2019 we have enrolled 10 patients in the study (50% enrollment completed).

Fourth Quarter Corporate Highlights:

Financial Results for the Year Ended December 31, 2019 and Recent Updates

For further details on BrainStorms financials, including financial results for the year ended December 31, 2019, refer to the Form 10-K filed with the SEC today.

Conference Call on Tuesday, February 18th @ 8:00 am Eastern Time

The investment community may participate in the conference call by dialing the following numbers:

Those interested in listening to the conference call live via the internet may do so by visiting the Investors & Media page of BrainStorms website at http://www.ir.brainstorm-cell.com and clicking on the conference call link.

A webcast replay of the conference call will be available for 30 days on the Investors & Media page of BrainStorms website:

About NurOwnNurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

About BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwnCellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement as well as through its own patents, patent applications and proprietary know-how. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(U.S.FDA) and theEuropean Medicines Agency(EMA) in ALS. Brainstorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S.FDAapproval of autologous MSC-NTF cells in ALS. Brainstorm received U.S.FDAclearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) inDecember 2018and has been enrolling clinical trial participants sinceMarch 2019. For more information, visit the company'swebsite.

Safe-Harbor StatementStatements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Corporate:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: 646-666-3188uri@brainstorm-cell.com

Investor Relations:Preetam Shah, MBA, PhDChief Financial OfficerBrainStorm Cell Therapeutics Inc.Phone: 862-397-8160pshah@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

BRAINSTORM CELL THERAPEUTICS INC.

CONSOLIDATED BALANCE SHEETSU.S. dollars in thousands(Except share data)

BRAINSTORM CELL THERAPEUTICS INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSSU.S. dollars in thousands(Except share data)

See the rest here:
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2019 Conference Call and Webcast @ 8:00 am Eastern...

Recommendation and review posted by Bethany Smith

SIOUX CITY (KTIV) - For five years now, the Ruehle family has held a teddy bear drive in memory of Mike Ruehle, who passed from cancer in 2014.

The teddy bears are given to adults and children with a cancer connection, in Mike's memory.

Family and friends knew Mike as "Bear."

The family asks people to consider donating a teddy bear in memory of a loved one, or in honor of healthy family members.

If you'd like to donate, every bear must be new with the tag still attached. The donations will stay in Siouxland.

There are five different locations where you can drop off the bears:

Ruehle's family says the teddy bear drive has donated more than 3,000 stuffed animals to several Siouxland agencies.

But who is the man who inspired the teddy bear drive?

"Very thoughtful person, very giving, he always took the time to listen to other people, just a really compassionate, kindhearted person," said Kerry Ruehle, Mike's Widow.

Mike Ruehle, or as his family called him, Bear, passed away six years ago, after a 12 year battle with cancer.

The family said he was very active in the community and was often coaching numerous sports teams.

They said he had a big heart, and always did what he could to make others feel better, even while he himself had cancer.

"If there were any patients his doctor had, who were having a difficult time with the news or with the adjustment. He would reach out to my dad, and see if my dad would sit down with them and talk about what was going on with them," said Rhett, Mike's son.

Part of the reason the teddy bear drive was started was because of Bear's compassion towards children who were also dealing with cancer.

"He would see a young child going through similar things that he was going through. He would always go out of his way to talk to that little kid and brighten their day a little bit," said Rhett.

Mike had had three different kinds of cancers, and due to the chemotherapy, eventually was diagnosed with MDS, which is a bone marrow failure disorder.

Doctors determined that the best treatment would be a stem cell transplant. The transplant surgery went well, but months later his body began rejecting his brother's stem cells, and within five weeks he had passed away.

"It was a shock because he had been ahead of schedule and everything else. And he had come through things beautifully, so it was quite a shock. But it was god's plan I guess," said Kerry.

But Mike's family wanted a way to keep Mike's memory alive, and that's what also helped start the teddy bear drive.

"My oldest granddaughter is five, she never met her grandpa. But in some ways, she feels as though she did, because of talking about him and she helps me with the bear drive," said Kerry

Read more:
Family honors the memory of loved one by collecting teddy bears for families dealing with cancer - KTIV

Recommendation and review posted by Bethany Smith

The latest market report published by Credence Research, Inc.GlobalBone Marrow Transplantation Market Growth, Future Prospects, Competitive Analysis, 2018 2026,

Access Free Sample Copy of Research Report @ https://www.credenceresearch.com/sample-request/59660

Market Insights:

Blood cancer is characterized by overproduction of an irregular type of blood cells, resulting in the overproduction of normal cells in the bone marrow preventing normal cells from performing important functions. According to the study references issued by Bristol-Myers Squibb Company by 2040 nearly 1,100,000 people will die from blood cancer, which will account for 7 percent cancer deaths.

Allogeneic bone marrow transplant are reigning the market. The inherent features associated with allogeneic procedures are the graft is free from contaminated tumor cells. Immune graft versus malignancy effect is produced by the immunocompetent cells derived from healthy donor. Low risk of disease recurrence and significant rise in the number of healthy donors drive the allogeneic bone marrow transplantation market growth. Autologous procedure will grow at a rapid pace in the near future due to rise in number of stem cell banks, which store healthy cells from patients and after conditioning treatment are introduced in them to produce healthy blood cells.

Lymphoma is dominating the indication segment for bone marrow transplantation market. There are 2 types Hodgkin lymphoma and Non-Hodgkin lymphoma. The primary factors responsible for its supremacy are significant rise in the patients newly diagnosed with Hodgkin lymphoma and excellent survival rate in patients post bone marrow transplantation procedure. Leukemia is the abnormal high production of white blood cells by the bone marrow. Technological advancement in the bone marrow transplantation technique will reduce the disease recurrence in leukemia patients receiving stem cell therapy.

Access Free Sample Copy of Research Report @ https://www.credenceresearch.com/sample-request/59660

North America is presently the leading regional segment for bone marrow transplantation market with a market share of 38%. The major factors responsible for its significant growth are rising prevalence of chronic lymphocytic leukemia and presence of sophisticated healthcare infrastructure. Europe with a market share of 32% is at second position owing to significant rise in the number of myeloma patients and domicile of major players such as PromoCell GmbH, Merck Millipore Corporation and Lonza Group Ltd. Asia Pacific with a market share of 20% will grow at a faster pace in the near future on account of technological advancement in bone marrow transplantation technique and proactive government policies to curb the mortality rate associated with blood cancer.

Biotechnology firms actively engaged in bone marrow transplantation procedures are AllCells LLC., Conversant Bio., Cellular Dynamics International, Gamida Cell Ltd., Hemacare Corporation, Lonza Group Ltd., Merck Millipore Corporation, Mesoblast Ltd., PromoCell GmbH and STEMCELL Technologies.

Key Market Movements:

Browse the full reportBone Marrow Transplantation Market athttps://www.credenceresearch.com/report/bone-marrow-transplantation-market

About Us:

Credence Researchis aworldwide market research and counseling firm that serves drivingorganizations, governments, non-legislative associations, and not-for-benefits.We offer our customers some assistance with making enduring enhancements totheir execution and understand their most imperative objectives. Over almost acentury, weve manufactured a firm extraordinarily prepared to this task.

Contact:

CredenceResearch Inc

Name: ChrisSmith (Global Sales Manager)

E-mail: sales@credenceresearch.com

Ph: 1-800-361-8290

Web:https://www.credenceresearch.com

See the rest here:
Bone Marrow Transplantation Market: Lower risk of disease recurrence and significant rise in the number of healthy donors drive the market growth -...

Recommendation and review posted by Bethany Smith

The global Acromegaly Treatment market is driven by the growing prevalence of the genetic disease, changing lifestyle. Also, factors such as rising incidence of hormonal diseases, such as hypopituitarism and endocrine diseases, and high demand for the advanced treatment is expected to increase the demand for Acromegaly treatment market.

Factors, such as unavailability of precise treatment and high cost of the surgery can restrain the market growth.

Some of the key players operating in this market include Pfizer Inc., Chiasma Inc., Novartis AG, Ipsen Biopharmaceuticals Inc., Wockhardt Ltd., Troikaa Pharmaceuticals Limited, GlaxoSmithKline plc, Aegis Therapeutics LLC, Crinetics Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Peptron Inc, among others.

You can get a sample copy of this report @ https://www.orianresearch.com/request-sample/804039

Increasing government support, favorable government insurance policies and schemes for the patients and rapid developments in technology will offer lucrative opportunities.

Based on Application, the Acromegaly Treatment market is segmented into Hospitals, Clinics, and others.

Based on Disease Types, the Acromegaly Treatment market is segmented into Ectopic Acromegaly, Pseudo Acromegaly.

Regionally, North America was the largest revenue generator in the Acromegaly Treatment market in 2017, because of high investments in research and development activities to investigate the applications of Acromegaly Treatment market.

Key Benefits of the Report:

* Global, Regional, Country, Application, and Disease Types Market Size and Forecast from 2014-2025

* Detailed market dynamics, industry outlook with market specific PESTLE, Value Chain, Supply Chain, and SWOT Analysis to better understand the market and build strategies

* Identification of key companies that can influence this market on a global and regional scale

* Expert interviews and their insights on market shift, current and future outlook and factors impacting vendors short term and long term strategies

* Detailed insights on emerging regions, Application& Disease Types, and competitive landscape with qualitative and quantitative information and facts.

Global Acromegaly Treatment Industry 2020 Market Research Report is spread across 121 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Inquire more or share questions if any before the purchase on this report @ https://www.orianresearch.com/enquiry-before-buying/804039

Target Audience:

* Acromegaly Treatment providers

* Traders, Importer and Exporter

* Raw material suppliers and distributors

* Research and consulting firms

* Government and research organizations

* Associations and industry bodies.

Research Methodology

The Market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective like analyst report of investment banks. The secondary research forms the base of our study where we conducted extensive data mining, referring to verified data sources such as government and regulatory published materials, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factor, investment, Market dynamics including technical scenario, consumer behavior, and end use industry trends and dynamics , capacity Production, spending were taken into consideration.

We have assigned weights to these parameters and quantified their Market impacts using the weighted average analysis to derive the expected Market growth rate.

The Market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs) which typically include:

* Original Manufacturer,

* Application Supplier,

* Distributors,

* Government Body & Associations, and

* Research Institute.

Order a Copy of Global Acromegaly Treatment Market Report @ https://www.orianresearch.com/checkout/804039

Table Of Content

1 Executive Summary

2 Methodology And Market Scope

3 Acromegaly Treatment Market Industry Outlook

4 Acromegaly Treatment Market Type Outlook

5 Acromegaly Treatment Market Application Outlook

6 Acromegaly Treatment Market Regional Outlook

7 Competitive Landscape

End Of The Report

Disclaimer

Customization Service of the Report:Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us:

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Excerpt from:
Acromegaly Treatment Industry 2020 Global Market Size, Demand, Growth Prospects, Key Insights, Top Companies and Forecast till 2025 - Instant Tech...

Recommendation and review posted by Bethany Smith

CLEVELAND Too bad there isnt some magic pill we could take to make the dream of sleep a reality.

One popular supplement that a lot of people take to deal with sleep issues is melatonin.

Melatonin is a hormone that our body produces naturally to help promote sleep. Most people can produce enough melatonin on their own, but there are some cases where it may be helpful to take a supplement.

The 3News Go! team reached out to Michelle Drerup, PsyD from the Cleveland Clinic's Sleep Disorders Center to find out more about melatonin. Dredrup is a sleep psychologist and behavioral sleep medicine specialist, who specializes in treating conditions like insomnia, circadian rhythm disorders, sleep apnea and more.

Sleep problems are very common. In fact, Drerup says about 10 percent of the population has symptoms of an insomnia disorder that impacts their daily functioning.

Dredrup also says theres not a lot of data out there on the efficacy of using melatonin at bedtime, but it may help you fall asleep.

RELATED: Do I have sleep apnea? Here are the symptoms to watch for

RELATED: 'Being fatigued is no different than being drunk' | Father shares story after sleepy driver fatally crashes into wife on Ohio Turnpike

Melatonin is a hormone of darkness," she says. "We call it the vampire hormone. It doesn't help with sleep maintenance or staying asleep, but more so it has some benefit for sleep onset for some people, as well as those who have delayed sleep phase disorder.

Dredrup says melatonin can also help for people dealing with jet lag.

But with so many different dosage options available, how do you know where to start?

Dredrup says, start with as small of a dose as possible.

I usually do not recommend higher than anything than 3mg. It doesn't tend to be effective at higher dosages for most people and it will just tend to make them feel groggy.

If youre considering using melatonin to help you fall asleep, its also a good idea to check with your doctor. Melatonin can interact with some medications, like blood pressure and diabetes drugs.

Link:
The vampire hormone: What you need to know about melatonin - WKYC.com

Recommendation and review posted by Bethany Smith

Dr. Amauri Caversan, ND, a Naturopath in Toronto, and his practice, the Dr Amauri Wellness Centre, has published a blog post about the thyroid, the diseases that affect the thyroid, and some Naturopathic approaches which may help with thyroid function. The thyroid is an essential organ in the human body, located in the neck. Its shaped like a butterfly and releases hormones that work to regulate energy levels, metabolism, muscle control, fertility, and much more.

Because the thyroid and the hormones it releases have such broad ranging effects in the body, thyroid difficulties can be a cause for serious concern, which is why its very important to maintain healthy thyroid function. Thyroid dysfunction may lead to a number of symptoms, including constipation, weight gain, unbearable fatigue, weakness, and problems with memory. The most common thyroid issues are either that the thyroid is under functioning, as in hypothyroidism, or over functioning, as in hyperthyroidism.

The thyroid produces two main hormones, known as T3 and T4, both of which are essential to the metabolic function of cells. When the thyroid is underperforming, or not creating the amount of hormones that the body needs, the bodys metabolism is compromised. This can cause a range of symptoms including fatigue, memory problems, mood swings, depression, weight gain, muscle cramps, and cholesterol elevation. The most common cause of hypothyroidism is Hashimotos thyroiditis, an autoimmune disorder in which the bodys immune system treats the thyroid like a threat. The immune system creates antibodies which prevent the thyroid from creating sufficient hormones for the body to function. Because the symptoms of hypothyroidism can be so severe, it is very important for people experiencing hypothyroidism to seek treatment to maintain their thyroid hormone levels at a healthy level.

One point discussed by the blog post is Naturopathic Medicine for thyroid function. The clinic offers a range of naturopathic treatments which may provide some benefits to thyroid health. Whether a person has hypothyroidism or the equally serious hyperthyroidism, the Dr. Amauri Wellness Centre would like them to consider a visit to a naturopath to discuss their condition.

The diagnosis of thyroid disorders is generally conducted through blood work or a thyroid ultrasound. Blood tests may include TSH, Free T4, Free T3, Reverse T3, thyroid peroxidase and anti-thyroid antibodies. TSH is the hormone produced by the pituitary gland that signals to the thyroid that it needs to produce more hormones. The level can indicate whether the body has enough thyroid hormones, too much or too little. Free T3 and Free T4 measure T3 and T4 and can be indicative of a thyroid disorder, but generally are not used on their own for diagnosis. Thyroid peroxidase and anti-thyroid antibodies are tested to determine if the thyroid disorder is caused by an autoimmune disorder.

Anyone looking for a Toronto-based Naturopath interested in learning more about Dr Amauri Caversan, ND and his naturopathic practices can visit his website or contact his office. The office offers a number of treatments that could offer some benefit in the case of thyroid disorders, including thyroid replacement therapy with natural dessicated thyroid hormones and recommendations for diet changes and supplement additions. Dr Amauri Wellness Centre may also suggest herbal formulas or IV therapy.

In addition to offering services for patients who may be dealing with thyroid disorders, Dr Amauri Caversan, ND and his clinic offer a number of other naturopathic treatments for people with a variety of issues as well as those who are just interested in their general wellness. Some of these treatments include acupuncture, cold laser treatments, naturopathic manipulation, and shockwave therapy. The Dr Amauri Wellness Centre caters a number of their services to people suffering from chronic pain, which often persists in spite of many attempts at treatment. Dr Amauri Caversan, ND does his best to understand each patients individual situation, because he understands that every situation is unique and no two people will respond in exactly the same way to exactly the same conditions.

People can visit the naturopathic clinic located at 1200 Bay Street #1102, Toronto, ON M5R 2A5, or call (416) 922-4114 for further inquiries.

###

For more information about Dr. Amauri Wellness Centre, contact the company here:

Dr. Amauri Wellness CentreDr. Amauri Caversan, ND(416) 922-4114info@dramauriwellnesscentre.comDr. Amauri Wellness Center1200 Bay Street #1102Toronto, Ontario M5R 2A5

More:
Naturopathic Clinic In Toronto Recommends These Naturopathic Approaches To Help Correct Thyroid Function - Press Release - Digital Journal

Recommendation and review posted by Bethany Smith

These days, you can chart cultural change through public loos.

In Los Angeles, gone are the bold-print doorsigns that say gender neutral restroom, complete with baffling stick men/women dressed in the kind of half-skirt, half-trouser ensembles that belong on a Jean Paul Gaultier runway; the interlinked Mars and Venus symbols with pompous explanatory small print welcoming everyone, regardless of gender or expression. Thanks, guys, but its a bathroom none of us are planning to stay long enough to feel the love.

Today, the signs simply read: We Dont Care. Or, my personal favourite: Whatever. Just wash your hands.

However, in the UK, when it comes to bathroom signs, there is no such levity. Were still desperately contorted about trans and gender issues and a long way from levelling out a debate that, I fear, hasnt yet reached peak insanity.

I thought wed peaked last year, when Always, the sanitary towel company, agreed to remove the Venus symbol from its wrapping after the trans lobby complained that not everyone who has periods identifies as a woman.

I thought wed peaked when the police were forced to reveal that convicted rapists were allowed to be logged as female when arrested, if that is how they choose to identify themselves. When the BBC promoted an educational short film telling nine-year-olds that there were over 100 genders, that had to be it?

Surely we peaked last January, when former policeman Harry Miller was visited by police after tweeting transphobic comments (such as: I was assigned mammal at birth, but my orientation is fish. Dont mis-species me)? Miller claimed that the Humberside Police officer who interviewed him had said hed committed no crime, but we need to check your thinking.

Which is Orwellian enough but after Miller discovered his tweet incident had been entered onto his police record, as a non-crime hate incident, he launched legal action so that a court might establish once and for all that he had not broken any law. The police probe was decreed unlawful by the High Court on Friday.

But this is no time to celebrate, thanks to the opposition Labour Party, which, in the midst of its leadership contest, is busy descending into a farcical civil war over transgender rights.

A controversial pledge card calling on the party to expel transphobic members has exposed a faultline running through the movement between and those who sign up wholeheartedly to the trans-activist insistence that transwomen are women, and seasoned Left-wing feminists, who worry about proposed reforms to make it simpler to transition legally and, thus, access all-female spaces such as changing rooms and toilets.

Out there in the Labour heartlands, these are not the issues keeping voters up at night. Its as if the party has learnt nothing from Trump or Brexit or from Jo Swinson, the headmistressy and super-woke former Liberal Democrat leader whose election campaign went up in smoke on the altar of transgender ideology.

But all of this pales in importance beside an easily missed news item tucked away in this weekends Sunday papers. One headline ran: NHS endorsing guide for transgender patients that approves puberty blockers and declares anatomy is not always a good guide to determining a childs sex.

The NHS has already tarnished itself over matters of gender. More than once, the scandal-hit Tavistock Clinic, the countrys only NHS gender identity service for children, has found itself in the eye of the storm after accusations that it was fast-tracking young people into changing gender and offering children as young as 11 hormone-blocking drugs. But at least this shockingly proactive approach has been limited to patients within the clinic until now.

A number of NHS trusts across the south west are to send out a Supporting Trans People toolkit, written by trans campaigners and branded with NHS logos, that declares that anatomy is not always a good guide to determining a childs sex. It also condones the use of puberty blockers on adolescents, drugs that are, at present, licensed in the UK only to treat children who start puberty abnormally early, not those just questioning their gender identity.

Both the Royal College of Paediatrics and Child Health and NHS England have ordered national reviews into the ethics of prescribing such treatment.

Its the inherent contradictions in PC-culture-gone-mad that I cant get past. Because if you pare down the argument for hormone blockers, its all about protecting youngsters mental health a mental health that could understandably suffer if someone felt trapped in the wrong body for years.

So what do we do? We pump them full of drugs that keep them in that state, preventing their natural sex hormones, oestrogen and testosterone, from kicking in.

Its official: weve hit new levels of gender insanity.

Read Celia Walden at telegraph.co.uk every Monday, from 7pm

Read the original here:
Weve finally hit peak insanity over trans havent we? - Telegraph.co.uk

Recommendation and review posted by Bethany Smith

When Tyler Wilson came home after his deployment in Afghanistan in 2005, he was paralyzed from the waist down. He had been shot four times and still had a bullet lodged in his spinal cord.

Ten years later, when he and his wife, Crystal, decided to start a family, they needed medical assistance. But insurance didnt cover their surgical or hormone treatments. Neither did the Veterans Administration.

They basically said, thank you for your service, Tyler said, but youre on your own for this one.

When they got the bill for the first round of treatment, it was $40,000. Four rounds of treatment, and thousands of dollars later, they have two boys Matthew, 3, and 6-month-old Michael.

The Wilsons now are trying to make sure other people dont have to struggle so hard financially to start a family, working with lawmakers and other individuals to get The Colorado Building Family Act passed at the state Capitol.

House Bill 1158 would require insurance companies to cover the most effective treatment for infertility, called in vitro fertilization (IVF) where the egg and sperm are fertilized in a lab then transferred into the uterus. The expanded coverage would also include the harvesting and freezing of eggs and sperm for people undergoing medical treatment that threatens fertility, such as chemotherapy.

Income should not be a barrier for becoming a parent, said Rep. Leslie Herod, a Denver Democrat who is helping lead the charge on the bill. The treatment is out there, we just have to make it accessible and affordable.

The bill passed unanimously in the House Health and Insurance Committee on Wednesday, after hours of testimony from individuals and couples including the Wilsons who struggle with infertility, and the hefty costs associated with its treatment.

No one spoke out against the bill, though a handful of insurance companies are monitoring the bills outcome.

Amanda Massey, executive director of the Colorado Association of Health Plans, a trade group that represents insurance companies, says her organization is neutral on the measure, but warned that the expansion of coverage will likely increase insurance premiums.

We are really just here to remind legislators that this has a cost, Massey said, adding that this bill would impact approximately one third of Colorado health plans.

A data analysis done by Californias Health Benefit Review Program for Californias State Legislature last year estimated that including IVF treatment in insurance coverage would increase individual monthly premiums by $2.76 for the state plan and $3.72 for the small group market.

But similar data appears to be lacking for Colorado.

Since the 1980s, 16 states have passed laws that require insurers to cover fertility diagnosis and treatment, according to the National Conference of State Legislatures.

In Colorado, insurance companies are required to cover X-rays and diagnostic lab procedures related to infertility. Insurance must also include coverage for artificial insemination, with the typical procedure being intrauterine insemination (IUI) where sperm is inserted directly into the uterus by a doctor.

A woman under 35 has only a 25% chance of getting pregnant from IUI, after three rounds of treatment. For women over 40, that drops down to a 15% chance, according to Dr. Sara Barton, an infertility expert at the Colorado Center for Reproductive Medicine.

So its largely an ineffective treatment, but its the one that insurance companies will cover, Barton said during testimony. IVF, she said, has a 65% success rate on the first round of treatment.

So I definitely understand the fact that premiums may go up a little bit. However, what I want to educate people on is the fact that, because insurance is not covering it, there are long-term, downstream costs that are causing riskier health decisions for both moms and babies, Crystal Wilson said.

The bill also aims to help individuals undergoing medical treatment like chemotherapy have biological children in the future by preserving eggs and sperm.

If this was covered by insurance, I would have been able to have kids, said Carley Rutledge, a 25-year old film producer based in Denver who spoke in support of the bill. Rutledge was diagnosed with bone cancer when she was 16, but was unable to preserve her eggs before receiving chemo.

Around 2,000 people in Colorado between the ages of 15 and 44 are diagnosed with cancer each year, according to Dr. Leslie Appiah, a doctor who specializes in infertility and reproductive health problems at the University of Colorado Anschutz Medical Campus.

For males under 18, 66% of them will experience difficulty with testicular function after cancer treatment. And 40% of women from ages 18 to 39 will be less likely to conceive after cancer treatment.

For state Rep. Kerry Tipper, a Democrat from Lakewood who is also sponsoring the bill, the topic is deeply personal.

Tipper and her husband have been trying to get pregnant for over four years.

Weve always envisioned being parents. The house we bought, the life weve built everything has centered around us building a family, Tipper said. And to know that that might not happen was devastating. But we have hope, because the majority of people that get treated have success and we are really good candidates for the treatment.

Last session, Tipper had three artificial inseminations. And so far this session, shes had two more. She says her experience has been hard to talk about and it has left her feeling isolated.

But these are issues that can be overcome a lot of the time, she said. And a lot of times, its just an issue of cost. And to me, its unfathomable that you have someone with a medical diagnosis and they cant access a cure because of the cost. And we know that in other states thats not an issue.

To help pay for their infertility treatment, the Wilsons created a GoFund me account to pool money from friends, family and sympathetic strangers. And they applied to a handful of grants, two of which they received. But still, the fertility treatment for their first son cost them $14,000 out of pocket. To conceive their second child, it took three more rounds of treatment.

Read more health stories from The Colorado Sun

Tipper says she and her husband havent encountered the cost barriers that a lot of people face. They have health coverage through her husbands company, which is based in Massachusetts, where insurance companies are required to cover infertility treatment.

And even though we have insurance, we still pay a lot of money out of pocket for it, she added.

What I realized early on is that what people do when they dont have insurance coverage is they go into debt. They get second mortgages on their house. They max out their credit cards. They work three jobs. All so they can have a family, said Tipper.

Which adds a lot of stress, and makes it even harder to get pregnant, she says.

Infertility is also still a really stigmatized topic, Tipper said. We dont talk about it a lot, and it can be so isolating for people.

She said when she started drafting the bill, she was overwhelmed by how many individuals reached out to share their difficult fertility stories.

Weve had [legislative] aids telling their representatives that theyve struggled with this issue and representatives who have shared in confidence with us that they struggle with this too, Tipper said.

There are so many people, even in this chamber, that have been impacted by this issue.

The Wilsons frequently speak about their struggles with infertility and the lack of insurance coverage for such. In 2016, they traveled to Washington to lobby Congress to include IVF treatment in military insurance coverage.

The VA now covers some infertility treatment, but the criteria couples have to meet is stringent, Crystal said. The Wilsons were denied and had to appeal their case nine times before they finally received assistance from the VA for treatment to have their second son. But the IVF failed, and they had to do the process again at a different clinic.

We want to make sure that anybody that is diagnosed with infertility after us dont have to fight like we did, Crystal Wilson said. We dont want other people, years or generations down the line, to have to fight the same fight.

Crystal said that the conversation at Colorados Capitol on Wednesday felt different.

The fact that every single representative on the committee voted in favor of the bill was, honestly, to my recollection, has never happened in any other state, and in D.C., it definitely didnt happen, Crystal Wilson said.

Rep. Perry Will, a Republican from New Castle, choked up while trying to express his support for the bill. My grandkids are the most important thing that God gave me, he said.

Later, he shared with The Colorado Sun that his daughter struggled for years to get pregnant. And fertility treatment helped give him a grandchild. Now he has three.

Infertility is a bipartisan issue, Will said. It impacts everyone. Its about family.

The bill now heads to the House Appropriations Committee for its next hearing. If signed into law, the legislation would take effect on Jan. 1, 2022.

Updated at 8:05 a.m. on Feb. 14, 2020: This story was updated to correct attribution of a quote. Dr. Sara Barton, testifying about the effectiveness of artificial insemination techniques, said So its largely an ineffective treatment, but its the one that insurance companies will cover.

An earlier version of the story also misidentified the home cities of two lawmakers, Rep. Leslie Herod, a Democrat from Denver, and Rep. Perry Will, a Republican from New Castle. Also, the status of House Bill 1158 was described incorrectly. It next heads to the House Appropriations Committee.

This reporting is made possible by our members. You can directly support independent watchdog journalism in Colorado for as little as $5 a month. Start here: coloradosun.com/join

Read more:
One in eight people struggle with infertility. Colorado lawmakers want insurance to cover treatment - The Colorado Sun

Recommendation and review posted by Bethany Smith

So many noticeable things happen when you lose weight your clothes fit better, you have more energy and you may even feel more confident. But what is actually happening inside your body when the scale ticks down?

The benefits of losing 10 pounds go far beyond appearance.

Credit: LIVESTRONG.com Creative

Well, quite a lot, as it turns out. And these positive changes might start sooner than you think. In fact, when you lose just 10 pounds especially if you're overweight it can kickstart a whole host of bodily shifts toward better health.

To fully understand the biology of weight loss would take the equivalent of 30 semester hours. To save you the trouble of enrolling in university, here's a brief explanation of what's really happening in your body during the early stages of weight loss and the benefits of losing 10 pounds.

You gain weight when you eat more calories than your body needs to support its basic functions think: respiration and digestion and energy output, including exercise. Your body converts these excess calories to fat and stores it in your fat cells for later, just in case there's a shortage.

When that shortage doesn't come, and when you continue to exceed your calorie needs, more and more fat is stored in your fat cells, which begin to grow larger and larger. This is the reason your pants seem to get smaller and smaller.

But when you start to lose weight, the opposite happens.

"Dieting produces a condition of negative energy balance, where energy in is less than energy expended. The body must then use stored energy to survive, which primarily comes from our fat cells," Joseph Houmard, PhD, director of the human performance laboratory and professor of kinesiology at East Carolina University, tells LIVESTRONG.com. "With this 'stress' of negative energy balance, hormones in the bloodstream magnify the ability of the fat cells to release stored fat to be used for energy in other tissues."

As this happens, your fat cells shrink and your pants seem to get bigger and bigger.

This doesn't happen immediately, though. According to authors of a research review published in the Journal of the Academy of Nutrition and Dietetics in March 2014, during the early stage of weight loss the body is primarily burning stored carbohydrates and protein as well as a considerable amount of water.

This early phase lasts several days or weeks, until the body shifts to burning fat for energy. You can expect your fat cells to start whittling away by the time you reach the 10-pound mark, though, which means you'll start noticing changes in the mirror.

A drop in blood pressure is one of the positive things that happen when you lose 10 pounds.

Credit: annebaek/iStock/GettyImages

Beyond being able to wear skinny jeans, one of the most important reasons to lose 10 pounds or more is heart health.

Being overweight increases the volume of blood your body must circulate through your blood vessels, which increases strain on the arteries, according to the Mayo Clinic. Over time, high blood pressure can lead to a narrowing and hardening of the arteries, affecting their ability to carry fresh, oxygenated blood to the heart. This increases the risk of heart attack, stroke and heart disease.

The good news is that your blood volume decreases quite quickly when you start to lose weight. "The efficiency of weight loss is quite remarkable, with as little as 2 pounds of weight loss producing a one point drop in blood pressure," Dr. Houmard says. "Thus, relatively modest amounts of weight loss in the range of 4 to 8 pounds can decrease blood pressure by 3 to 8 points, which is significant in terms of reducing risk for heart disease and other conditions."

Just how weight loss reduces blood pressure is complex. According to Dr. Houmard, it has to do with a combination of changing hormones, better kidney function and a decreased strain on the heart.

Other mechanisms behind decreasing blood pressure and blood volume involve terms like "natriuretic peptides" and "renin-angiotensin-aldosterone." But by now you get the basic idea without going into full-on geek mode.

Hormones are your body's Uber. They carry chemical messages through your bloodstream and tissues that affect things like your metabolism, growth and development, reproduction, sexual function and mood. But excess body fat can affect the normal functioning of hormones, according to Harvard Health Publishing, and the processes they affect that are crucial to health.

A wealth of research, including a study published in the Journal of Clinical Oncology in July 2012, has shown that being overweight or obese can increase a woman's risk of hormone-receptive breast cancer. According to BreastCancer.org, the association isn't fully understood, but it's likely due to increases in hormones, including estrogen, that occur with excess weight.

"Estrogenically active fat is linked with breast cancer. If the fat a woman lost was fat that produced estrogen, then hormonal levels will decrease when that fat is lost. This is why weight loss is recommended to reduce the risk of breast cancer," explains Denise Pickett-Bernard PhD, RDN, LDN, a certified practitioner with the Institute for Functional Medicine.

Losing weight can help normalize hormone levels pretty quickly. In the 2012 Journal of Clinical Oncology study, the women lost 10 percent of their body weight, on average, during the 12-month trial, and markers of several estrogen-like hormones, as well as testosterone, decreased by between 10 and 26 percent.

Interestingly enough, whether the women lost the weight via diet only or by a combination of diet and exercise affected the results. Women who both dieted and engaged in regular exercise had much greater decreases in the potentially risky hormones.

It's not all good news, however. While potentially dangerous levels of some hormones change favorably, other unfavorable hormonal changes may take place, and these can affect your ability to lose 10 pounds and then keep the weight off. "Humans are hardwired to store body fat in case of a famine," says Pickett-Bernard. As explained in a research review published in the International Journal of Obesity in August 2015, our bodies tends to adjust to a calorie deficit in an effort to maintain homeostasis and hold onto fat stores.

To maintain status quo, levels of the appetite-stimulating hormone ghrelin increase, while levels of appetite-suppressing leptin decrease. These hormonal changes can persist even after you've reached your goal, making it difficult to sustain your weight loss.

When you lose 10 pounds via exercise, your muscles and calorie burn will change along with your weight.

Credit: vitapix/E+/GettyImages

If you lose 10 pounds with the help of exercise, your body will adapt, according to the Centers for Disease Control and Prevention. At the beginning of a new workout regimen, you're more likely to see fast results in muscle gain and fat loss. Your body is less conditioned, so you have to work harder, and you'll burn more calories than someone who is more conditioned doing the same activity.

The good news is you're getting fitter; the bad news is that you'll have to gradually progress the intensity, duration and/or frequency of your workouts to continue to achieve results.

Being overweight increases your chances of having a sleep disorder, and having a sleep disorder increases your chances of being overweight, say the authors of a March 2013 review in Nature of Science and Sleep. Talk about a double-whammy.

The good news is that losing 10 pounds can improve your sleep along with your risk factors for obesity. In a 2012 study by researchers at Johns Hopkins University School of Medicine, 77 volunteers who were either overweight or obese and who reported a variety of sleep disorders were divided into two intervention groups a weight-loss diet or a weight-loss diet plus exercise.

After six months, both groups had lost 15 pounds and 15 percent of their belly fat. As a result, both groups improved their overall sleep score by approximately 20 percent. Based on those findings, losing even 10 pounds is likely to help you sleep a lot more soundly.

See the original post:
What Really Happens to Your Body When You Lose 10 Pounds - LIVESTRONG.COM

Recommendation and review posted by Bethany Smith

Dublin, Feb. 17, 2020 (GLOBE NEWSWIRE) -- The "Stem Cell Therapy Contract Manufacturing Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study on contract service providers engaged in the development and manufacturing of stem cell therapies. The study features in-depth analyses, highlighting the capabilities of various stem cell therapy CMOs

Advances in the fields of cell biology and regenerative medicine have led to the development of a variety of stem cell-based therapies for many cardiovascular, oncological, metabolic and musculoskeletal disorders. Driven by the revenues generated from stem cell therapies, the regenerative medicine market is anticipated to generate revenues worth USD 100 billion by 2030.

With a promising pipeline of over 200 stem cell therapy candidates, it has become essential for developers to scale up the production of such therapeutic interventions. Given that stem cell therapy manufacturing requires highly regulated, state-of-the-art technologies, it is difficult for stakeholders to establish in-house expertise for large-scale manufacturing of stem cell therapies.

As a result, stem cell therapy developers have begun outsourcing their manufacturing operations to contract manufacturing organizations (CMOs). Specifically, small and mid-sized players in this sector tend to outsource a substantial proportion of clinical and commercial-scale manufacturing processes to contract service providers. In addition, even big pharma players, with established in-house capabilities, are gradually entering into long-term business relationships with CMOs in order to optimize resource utilization and manage costs.

According to a recent Nice Insight CDMO survey, about 55% of 700 respondents claimed to have collaborated with a contract service provider for clinical and commercial-scale product development requirements. Considering the prevalent trends, we believe that the stem cell therapy manufacturing market is poised to grow at a steady pace, driven by a robust pipeline of therapy candidates and technological advances aimed at mitigating challenges posed by conventional methods of production. Amidst tough competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor and is likely to grant a competitive advantage to certain CMOs over other players in the industry.

One of the key objectives of the report was to estimate the future size of the market. Based on parameters, such as increase in number of clinical studies, target patient population, anticipated adoption of stem cell therapies and expected variation in manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the mid to long term, for the period 2019-2030.

Amongst other elements, the report includes:

In order to provide a detailed future outlook, our projections have been segmented on the basis of:

Key Topics Covered

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Regulatory Landscape

6. Stem Cell Therapy Contract Manufacturers in North America

7. Stem Cell Therapy Contract Manufacturers in Europe and Asia-Pacific

8. Partnerships and Collaboration

9. Contract Manufacturing Opportunity Assessment

10. Capacity Analysis

11. Demand Analysis

12. Market Forecast

13. Key Performance Indicators

14. Concluding Remark

15. Executive Insights

16. Appendix 1: Tabulated Data

17. Appendix 2: List of Companies and Organizations

For more information about this report visit https://www.researchandmarkets.com/r/rktm8d

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

See the original post here:
Stem Cell Therapy Contract Manufacturing Industry, 2019-2030 - Availability of Cutting-Edge Tools & Technologies has Emerged as a Differentiating...

Recommendation and review posted by Bethany Smith

CRISPR Therapeutics (NASDAQ:CRSP) reported its fourth-quarter financial results on Wednesday afternoon, substantially beating revenue expectations and impressing both analysts and investors alike.

Fourth-quarter revenue grew to $77 million, a substantial increase from the mere $100,000 reported in Q4 2018. Total annual revenue came in at $289.6 million, while last year's income came in at a much smaller $3.1 million. While this surge is mainly due to collaboration agreements with Vertex Pharmaceuticals as opposed to product sales, it's still an impressive increase considering analysts had expected just $45.2 million for the quarter.

Image source: Getty Images.

Other financial metrics, such as CRISPR's cash position, have improved as well. By Dec. 31, cash and cash equivalents grew to $943.8 million, a 106.7% increase from the $456.6 million reported last year. The biotech company is also now reporting a net profit thanks to this revenue hike. Net income came in at $30.5 million, whereas last year CRISPR reported a net loss of $47.6 million in its 2018 fourth quarter.

CRISPR is developing four main treatments. CTX001 is a treatment for patients with sickle cell disease and transfusion-dependent beta thalassemia. Both of these are genetic blood disorders that impact the blood's ability to transport oxygen throughout the body.

The company's three other drugs, CTX110, CTX120, and CTX130, are types of cancer treatments known as CAR-T therapies. While other healthcare companies are developing their own CAR-T drugs, these types of therapies tend to be quite expensive. CRISPR's technology could make the development process for these types of drugs much cheaper than their competition.

See the original post here:
CRISPR Therapeutics Reports Q4 Earnings, Beats Revenue Expectations - The Motley Fool

Recommendation and review posted by Bethany Smith

PHILADELPHIA - Three patients with advanced cancer suffered no serious side effects from being treated at the University of Pennsylvania in the first U.S. clinical study of cells edited with CRISPR, the gene editing technology.

But neither did they benefit, according to results published this month in Science. One patient with a bone marrow cancer called multiple myeloma has died and another has progressed. A patient with sarcoma, a soft tissue cancer, also progressed.

Pilot clinical trials are designed to assess safety, not effectiveness. And the inaugural U.S. test of CRISPR-edited cells in humans was so ethically and scientifically fraught that Penn spent more than two years getting necessary approvals for the January 2018 launch.

Still, the experiment was intended to combine and improve on two revolutionary immune-boosting approaches that showed startling effectiveness even in early trials. One approach, which cuts a natural brake on the immune system, has led to a class of cancer drugs called checkpoint inhibitors. The other approach genetically engineers immune soldiers called T cells to recognize and attack cancer cells; the first approved T-cell therapy, Novartis' Kymriah, was pioneered at Penn and Children's Hospital of Pennsylvania.

Although the CRISPR-edited cells did not melt away tumors or stop cancer progression, the cells did survive and grow in patients for up to nine months. In a previous Penn clinical trial that used engineered T cells to attack multiple myeloma, half the cells were dead in a week.

Penn T-cell researcher Carl June, principal leader of the new study and previous groundbreaking work, sees the CRISPR trial as another incremental step in a medical odyssey. CRISPR technology was invented just eight years ago, yet the version used by Penn is already so outmoded that the trial has been discontinued.

"We learned what we wanted to learn," June said of the study, on which Stanford University collaborated. "It opens up the door for a lot of new approaches."

What they learned was mostly reassuring.

The difficult, many-step manufacturing process was feasible. CRISPR was used on T cells to cut out two genes, one that codes for the immune system brake, and another that could hamper the T cells' ability to latch onto cancer cells. CRISPR also inserted a gene that enabled the T cells to recognize and target a protein found on the cancer cells but not healthy cells.

These edits accidentally caused some unusual rearrangements of DNA in a small fraction of T cells - one of the biggest worries with CRISPR. But as the T cells took hold and multiplied in patients, these rearrangements steadily decreased, "suggesting that they conferred no growth advantage," the researchers wrote.

The edited T cells did not trigger any of the dangerous toxicities related to revving up the immune system that are common with checkpoint inhibitors and engineered T cells.

However, the researchers noted that a longer trial with more patients and higher doses will be needed "to fully assess the safety of this approach."

A problem that has occurred with engineered T-cell therapies also showed up in the CRISPR trial: one patient's cancer cells stopped making the protein, called NY-ESO-1, that the T cells had been edited to target.

In future trials, "we would not just use NY-ESO-1 because we've learned the tumor can live without it," June said. "We'd want to use multiple targets."

Renier J. Brentjens, an oncologist and cell therapy researcher at Memorial Sloan-Kettering Cancer Center in New York City, called the paper an important "proof of principle."

"The T cells persisted and found the tumors. It would have been nice to see remissions or tumor regression, but it doesn't necessarily mean the approach is flawed," Brentjens said. "It may be that the target they used is not sufficient."

(c)2020 The Philadelphia Inquirer

Distributed by Tribune Content Agency, LLC.

Continued here:
Study suggests editing human genes to fight cancer is safe. But does it work? - PostBulletin.com

Recommendation and review posted by Bethany Smith

CRISPR Therapeutics AG (CRSP) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to loss of $0.92 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 1,175%. A quarter ago, it was expected that this company would post a loss of $0.95 per share when it actually produced earnings of $2.40, delivering a surprise of 352.63%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

CRISPR Therapeutics AG, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $77.02 million for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 3.42%. This compares to year-ago revenues of $0.12 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

CRISPR Therapeutics AG shares have lost about 6.4% since the beginning of the year versus the S&P 500's gain of 3.9%.

What's Next for CRISPR Therapeutics AG?

While CRISPR Therapeutics AG has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for CRISPR Therapeutics AG was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$1.08 on $7.50 million in revenues for the coming quarter and -$4.65 on $30.04 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportTo read this article on Zacks.com click here.Zacks Investment Research

Read this article:
CRISPR Therapeutics AG (CRSP) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance

Recommendation and review posted by Bethany Smith

The CRISPR Technology market report [5 Years Forecast 2020-2025] focuses on Major Leading Industry Players, providing info like market competitive situation, product scope, market overview, opportunities, driving force and market risks. Profile the top manufacturers of CRISPR Technology, with sales, revenue and global market share of CRISPR Technology are analyzed emphatically by landscape contrast and speak to info. Upstream raw materials and instrumentation and downstream demand analysis is additionally administrated. The CRISPR Technology market business development trends and selling channels square measure analyzed. From a global perspective, It also represents overall industry size by analyzing qualitative insights and historical data.

The study encompasses profiles of major companies operating in the global CRISPR Technology market. Key players profiled in the report includes : Thermo Fisher Scientific, Merck KGaA, GenScript, Integrated DNA Technologies (IDT), Horizon Discovery Group, Agilent Technologies, Cellecta, GeneCopoeia, New England Biolabs, Origene Technologies, Synthego Corporation, Toolgen and among others.

Get Free Sample PDF (including full TOC, Tables and Figures) of CRISPR Technology Market @https://www.researchmoz.us/enquiry.php?type=S&repid2374634

This CRISPR Technology market report provides a comprehensive analysis of:Industry overview, cost structure analysis, technical data and competitive analysis, topmost players analysis, development trend analysis, overall market overview, regional market analysis, consumers analysis and marketing type analysis.

Scope of CRISPR Technology Market:

The global CRISPR Technology market is valued at million US$ in 2019 and will reach million US$ by the end of 2025, growing at a CAGR of during 2020-2025. The objectives of this study are to define, segment, and project the size of the CRISPR Technology market based on company, product type, application and key regions.

This report studies the global market size of CRISPR Technology in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of CRISPR Technology in these regions.

This research report categorizes the global CRISPR Technology market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors, customers, research findings & conclusion, appendix & data source and Porters Five Forces Analysis.

The end users/applications and product categories analysis:

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate foreach application.

On the basis of product,this report displays the sales volume, revenue (Million USD), product price, market share and growth rate ofeach type.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid2374634

(*Fill the form and our sales representative will get back to you for assistance)

CRISPR Technology Market The Regional analysis covers:

Key Takeaways and Reasons To Buy CRISPR Technology Market Report:

And Many More.Contact Us:

ResearchMozMr. Nachiket Ghumare,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email: [emailprotected]Follow us on LinkedIn @ http://bit.ly/2RtaFUo

Follow me on : https://marketnews-24.blogspot.com/

See the article here:
CRISPR Technology Market 2020 Trends, Emerging Technologies and Growth Analysis BY Forecast to 2025 - Nyse Nasdaq Live

Recommendation and review posted by Bethany Smith

EPS growth is an important number as it gives a suggestion of the future prospects of a company. It is usually expressed as a percentage and is then referred to as the EPS growth rate. Growth in EPS is an important measure of administration performance because it shows how much money the company is making for its investors or shareholders, not only because of changes in profit, but also after all the effects of issuance of new shares (this is especially important when the growth comes as a result of acquisition).

CRISPR Therapeutics AG, belongs to Healthcare sector and Biotechnology industry. The companys Market capitalization is $3.48B with the total Outstanding Shares of 437. On 14-02-2020 (Friday), CRSP stock construct a change of -3.99 in a total of its share price and finished its trading at 55.8.

Profitability Ratios (ROE, ROA, ROI):

Looking into the profitability ratios of CRSP stock, an investor will find its ROE, ROA, ROI standing at -2.6%, -2% and -40.7%, respectively. Return on assets (ROA) is a financial ratio that shows the percentage of profit a company earns about its overall resources. A performance measure used to estimate the efficiency of an investment or to compare the ability of some different investments. ROI measures the amount of return on an investment relative to the investments cost.

Earnings per Share Details of CRISPR Therapeutics AG:

The EPS of CRSP is strolling at -0.46, measuring its EPS growth this year at -101.6%. As a result, the company has an EPS growth of -1824% for the approaching year.

Given the significance of identifying companies that will make sure earnings per share at a tall rate, we later obsession to umpire how to identify which companies will achieve high amassing rates. One obvious showing off to identify high earnings per portion count together companies are to locate companies that have demonstrated such build up beyond the p.s. 5 to 10 years.

We cant have sufficient maintenance the once will always replicate the difficult, but logically stocks that have grown earnings per allowance strongly in the subsequent to are a fine bet to keep on to take effect as a result.

Analysts mean target price for the company is $74.96 while analysts mean suggestion is 2.2.

A beta factor is used to measure the volatility of the stock. The stock remained 6.36% volatile for the week and 4.49% for the month.

Historical Performance In The News:

Taking a look at the performance of CRISPR Therapeutics AG stock, an investor will come to know that the weekly performance for this stock is valued at 6.65%, resulting in a performance for the month at -6.31%.

Therefore, the stated figure displays a quarterly performance of 1.45%, bringing six-month performance to 21.04% and year to date performance of -8.38%.

P/S, P/E, P/C and P/B/ SMA50, SMA 200:

The price-to-sales is a valuation ratio that relates a companys stock price to its revenues. The price-to-sales ratio is a symbol of the value placed on each dollar of a companys sales or taxes. As of now, CRSP has a P/S, P/E and P/B values of 16.37, 0 and 5.17 respectively. P/E and P/B ratios both are used on a regular basis by the investor to measure the value of the company and to get the right amount of the share.

Its P/Cash valued at 5.53. The price-to-cash-flow ratio is a stock valuation indicator that measures the value of a stocks price to its cash flow per share

What do you mean by simple moving average (SMA)?

A simple moving average (SMA) is an arithmetic moving average calculated by adding the closing price of the security for some time periods and then dividing this total by the number of time periods. Its distance from 20-days simple moving average is 0.5%, and its distance from 50 days simple moving average is -8.64% while it has a distance of 11.83% from the 200 days simple moving average. The companys distance from 52-week high price is 437% and while the current price is 437% from 52-week low price.

See the original post:
Current Technicals:: CRISPR Therapeutics AG, (NASDAQ: CRSP) - NasdaqNewsFeed

Recommendation and review posted by Bethany Smith

Crispr Therapeutics AG (NASDAQ:CRSP) Equities researchers at Oppenheimer lowered their Q1 2020 earnings per share estimates for Crispr Therapeutics in a research report issued on Wednesday, February 12th. Oppenheimer analyst S. Tuerkcan now anticipates that the company will earn ($1.00) per share for the quarter, down from their previous forecast of ($0.89). Oppenheimer has a Outperform rating and a $80.00 price objective on the stock. Oppenheimer also issued estimates for Crispr Therapeutics Q2 2020 earnings at ($1.07) EPS, Q3 2020 earnings at ($1.16) EPS, Q4 2020 earnings at ($1.14) EPS, FY2020 earnings at ($4.38) EPS, FY2021 earnings at ($4.80) EPS, FY2022 earnings at ($5.90) EPS, FY2023 earnings at ($3.52) EPS and FY2024 earnings at $1.11 EPS.

Crispr Therapeutics (NASDAQ:CRSP) last announced its earnings results on Wednesday, February 12th. The company reported $0.51 earnings per share for the quarter, topping the consensus estimate of ($0.68) by $1.19. The business had revenue of $77.00 million for the quarter, compared to analysts expectations of $39.08 million. During the same period in the previous year, the company earned ($0.92) earnings per share. Crispr Therapeuticss quarterly revenue was up 76900.0% on a year-over-year basis.

Shares of CRSP opened at $55.80 on Monday. Crispr Therapeutics has a fifty-two week low of $30.75 and a fifty-two week high of $74.00. The firms 50 day moving average price is $57.63 and its 200 day moving average price is $53.03.

Several large investors have recently made changes to their positions in the business. Captrust Financial Advisors lifted its stake in shares of Crispr Therapeutics by 1,373.9% in the 4th quarter. Captrust Financial Advisors now owns 14,739 shares of the companys stock worth $874,000 after acquiring an additional 13,739 shares during the period. Cubist Systematic Strategies LLC lifted its stake in shares of Crispr Therapeutics by 672.8% in the 4th quarter. Cubist Systematic Strategies LLC now owns 47,140 shares of the companys stock worth $2,871,000 after acquiring an additional 41,040 shares during the period. First Republic Investment Management Inc. acquired a new stake in shares of Crispr Therapeutics in the 4th quarter worth $294,000. Marshall Wace LLP acquired a new stake in shares of Crispr Therapeutics in the 4th quarter worth $145,000. Finally, Bank of New York Mellon Corp lifted its stake in shares of Crispr Therapeutics by 17.1% in the 4th quarter. Bank of New York Mellon Corp now owns 46,167 shares of the companys stock worth $2,812,000 after acquiring an additional 6,736 shares during the period. 50.01% of the stock is currently owned by institutional investors.

In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total value of $465,000.00. Following the sale, the director now directly owns 7,500 shares of the companys stock, valued at approximately $465,000. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, President Rodger Novak sold 33,618 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. Corporate insiders own 21.40% of the companys stock.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Article: What is diluted earnings per share (Diluted EPS)?

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

See the article here:
Brokers Offer Predictions for Crispr Therapeutics AGs Q1 2020 Earnings (NASDAQ:CRSP) - Enterprise Echo

Recommendation and review posted by Bethany Smith